Please visit answersincme.com/YBC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the evidence for combining immune checkpoint inhibitors (ICIs) with chemotherapy in the treatment of advanced biliary tract cancer and provides a clinical perspective on the future role of these combinations in the treatment landscape. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating ICI plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Discuss the efficacy and safety of late-stage emerging ICI plus chemotherapy combinations being investigated for the first-line treatment of advanced biliary tract cancer, compared to conventional therapy options; and Summarize clinical considerations for the future use of emerging ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.